Atossa's FDA warning letter may mean new 510(k) application, but investors not too spooked
This article was originally published in Clinica
Executive Summary
Newly-public Atossa Genetics has been hit by a US FDA warning letter regarding the labelling of its mammary aspirate specimen cytology test (MASCT), which may require it to submit a new 510(k) application.